COVID-19 Vaccine (ChAdOx1-S [recombinant])

**VAXZEVRIA™**  
Supplier: AstraZeneca

**COVISHIELD**  
Supplier: Verity Pharmaceuticals

**INDICATIONS:**
- Individuals 18 years of age and older for dose 2 A, B
- See COVID-19 Vaccine Eligibility

These vaccines are not approved for use in those less than 18 years of age. C

**DOSES AND SCHEDULE:**
Adults 18 years of age and older: 2 doses given as 0.5 mL IM, 8 to 12 weeks apart. D, E, F

For individuals who are moderately to severely immunosuppressed (see COVID-19 Vaccine Eligibility), a 3-dose primary series is recommended. G The 3rd dose should be provided at least 28 days after the 2nd dose. Moderna COVID-19 vaccine is preferentially recommended for all doses in the primary series. If Moderna is unavailable, Pfizer-BioNTech can be given.

**NOTE:** A booster dose with a COVID-19 mRNA vaccine is recommended for individuals 18 years of age and older who have already received a primary COVID-19 vaccine series. See BOOSTER DOSES.

**ADMINISTRATION:**
- No reconstitution required.
- Following withdrawal of all available 0.5 mL doses, the residual vaccine from up to three vials may be withdrawn into the same syringe to constitute a full dose provided the vials are from the same manufacturer and the same lot number. See addendum for more information.

Storage and Handling:
- Unopened multidose vial:
  - +2°C to +8°C up to the end of its expiry date, kept in the original packaging and protected from light. Do not freeze.

---

A These vaccines are no longer being offered as a first dose, unless all other authorized COVID-19 vaccines are contraindicated or have been refused, due to the reduced effectiveness and the possible adverse effects specifically associated with viral vector vaccines (e.g., Thrombosis with Thrombocytopenia Syndrome [TTS]).

B Informed consent should include the risk and symptoms of Thrombosis with Thrombocytopenia Syndrome (TTS) versus the individual’s risk of serious illness from COVID-19, as well as the need to seek immediate medical care should symptoms develop.

C The minimum age for vaccine receipt is based on age at presentation (i.e., the vaccine may be offered to individuals on or after their 18th birthday).

D The two ChAdOx1-S vaccines are interchangeable within the vaccine series. NACI recommends that individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated.

E While the approved minimum interval between dose 1 and 2 is 4 weeks, the preferred interval is 8 to 12 weeks. If administration of the second dose is delayed, the series does not need to be restarted.

F The 2nd dose may be given with Janssen COVID-19 vaccine (Ad26.COV2.S [recombinant]) if AstraZeneca/COVISHIELD vaccine is not available; recipients should be advised that mRNA vaccine is preferable for a 2nd dose for those without a contraindication to mRNA vaccine because of improved protection against COVID-19.

G For individuals who received a single dose of Janssen vaccine, one additional dose of Moderna COVID-19 vaccine is recommended at least 28 days later.
COVID-19 Vaccine (ChAdOx1-S [recombinant])
VAXZEVRIA™ Supplier: AstraZeneca
COVISHIELD Supplier: Verity Pharmaceuticals

ADMINISTRATION (continued):

- Opened multidose vial:
  - After first vial puncture, the vaccine is stable at room temperature (up to +30°C) for 6 hours OR at +2°C to +8°C for 48 hours.
  - After the first vial puncture, the vial can be re-refrigerated, but the cumulative storage time at room temperature must not exceed 6 hours, and the total cumulative storage time must not exceed 48 hours. After this time, the vial must be discarded.
  - The vaccine can be pre-loaded into a syringe for up to 6 hours at room temperature (up to +30°C).
  - Ensure that the vial/syringe is clearly labelled with the date and time of first vial entry.
  - During use, vials/syringes may be handled in room light conditions.

BOOSTER DOSES:
A booster dose of a COVID-19 mRNA vaccine is recommended for individuals 18 years of age and older at least 6 months after the primary series has been completed. ▲

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of the vaccine or to any component of the vaccine. These individuals should be offered an mRNA COVID-19 vaccine and observed for at least 30 minutes after immunization.
2. History of thrombosis with thrombocytopenia following a previous dose of an adenovirus vector COVID-19 vaccine. These individuals should be offered an mRNA vaccine pending advice of the involved hematologist.
3. History of capillary leak syndrome.

PRODUCT COMPONENTS:
Potential allergens: polysorbate 80.
Other components: disodium edetate dihydrate, ethanol, L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, sucrose.

PRECAUTIONS:
- For individuals with suspected hypersensitivity or non-anaphylactic allergy to COVID-19 vaccine components, the vaccine should be administered in a controlled setting with expertise and equipment to manage anaphylaxis, with an extended period of observation post-vaccination of at least 30 minutes.
- Individuals who have experienced a previous cerebral venous sinus thrombosis (CVST) with thrombocytopenia, unrelated to adenovirus vector COVID-19 vaccination, or heparin-

▲ A 0.5 mL booster dose with a viral vector COVID-19 vaccine (i.e., AstraZeneca or Janssen COVID-19 vaccine) should only be considered when all other authorized COVID-19 vaccines are contraindicated or have been refused. Such clients should be informed that viral vector COVID-19 vaccines provide lower protection against infection with COVID-19, and that they are associated with rare but serious adverse effects (e.g., Thrombosis with Thrombocytopenia Syndrome [TTS], thrombocytopenia and Guillain-Barré syndrome) which have not been seen with the mRNA vaccines or Novavax COVID-19 vaccine.
COVID-19 Vaccine (ChAdOx1-S [recombinant])

VAXZEVRIA™  Supplier: AstraZeneca
COVISHIELD  Supplier: Verity Pharmaceuticals

PRECAUTIONS (continued):

- induced thrombocytopenia (HIT) should only receive this vaccine if the benefits outweigh the
  potential risks and an mRNA vaccine is unavailable.
- Wait until symptoms of an acute illness are resolved before vaccinating with COVID-19
  vaccine to differentiate symptoms of illness from vaccine side effects.
- Individuals diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C) or
  Adults (MIS-A) should delay COVID-19 vaccination until they have recovered from illness
  and for 90 days after the date of diagnosis of MIS-C or MIS-A.
- Additional doses of a COVID-19 vaccine should be deferred in those who experienced a
  physician-diagnosed myocarditis or pericarditis event following a previous dose of a COVID-
  19 mRNA vaccine. For guidance on how to proceed with further COVID-19 vaccination, see
  the PRECAUTIONS section of the Pfizer-BioNTech and Moderna
  product pages. Deferral is not required for those with a prior history of myocarditis or pericarditis that is unrelated to
  COVID-19 mRNA vaccines and are no longer being followed by a medical professional for
  heart issues.
- In individuals with a history of immune thrombocytopenia (ITP), the risks of developing low
  platelet levels should be considered before vaccination.

SPECIAL CONSIDERATIONS:

- COVID-19 vaccines can be administered concomitantly or at any time before or after the
  administration of another inactivated or live vaccine.
- Deferral of COVID-19 vaccination is no longer recommended for individuals who have
  received anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or
  prevention of COVID-19.
- A complete series of COVID-19 vaccine may be offered to individuals without
  contraindications who have recovered from confirmed SARS-CoV-2 infection.
- Recipients should practice public health measures for prevention of SARS-CoV-2 infection
  and transmission regardless of vaccination with COVID-19 vaccine, at this time.

ADVERSE EVENTS:

**Local**: pain, swelling, redness, pruritus.

**Systemic**: fatigue, headache, myalgia, chills, arthralgia, fever, malaise, nausea.

Very rare cases of Guillain Barré syndrome and immune thrombocytopenia (ITP) have been reported.

A potential increased risk of serious blood clots has been observed with most cases having
onset 4 to 28 days following receipt of the AstraZeneca or COVISHIELD vaccine. This adverse
event is being referred to as Thrombosis with Thrombocytopenia Syndrome (TTS) and is
estimated to occur in approximately 1 in 50,000 vaccine recipients. The frequency of TTS
following a second dose is currently reported as approximately 1 per 600,000. Symptoms
warranting medical attention include: headache beginning beyond 4 days after vaccination,
blurred vision, difficulty speaking, seizure, difficulty moving parts of the body, shortness of
breath, chest pain, new severe swelling, pain or colour change of an arm or a leg, persistent
abdominal pain, abnormal bruising, reddish or purple spots or blood blisters under the skin, or
bleeding beyond the site of vaccination.
COVID-19 Vaccine (ChAdOx1-S [recombinant])
VAXZEVRIA™ Supplier: AstraZeneca
COVISHIELD Supplier: Verity Pharmaceuticals

ADVERSE EVENTS (continued):
In addition, a very small number of cases of capillary leak syndrome have occurred in people who received AstraZeneca vaccine. Capillary leak syndrome is a very rare, serious condition that causes fluid leakage from small blood vessels (capillaries), resulting in swelling mainly in the arms and legs, low blood pressure, thickening of the blood and low blood levels of albumin (an important blood protein). As of May 27, 2021, more than 78 million doses of AstraZeneca have been administered in the EU/EEA and the UK, and 6 cases of capillary leak syndrome were observed within 4 days of vaccination; 3 of these cases occurred in individuals with a history of the syndrome.

REFERENCES:
1. AstraZeneca product monograph
2. COVISHIELD product monograph
3. National Advisory Committee on Immunization: Recommendations on the use of COVID-19 Vaccine(s)

ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose

Following withdrawal of all available 0.5 mL doses, a full 0.5 mL dose may be constituted from the residual vaccine volume from up to three separate vials, provided the vials are from the same manufacturer and same lot number. In order to minimize the risk of microbial contaminants and maintain product quality, the following processes should be followed:

- Only vials containing residual vaccine volume are to be used to prepare a full dose when using multiple vials to constitute a single dose. Residual volume should not be combined with contents from a different vial that still contains at least one full dose of the vaccine (to minimize the chance of contaminating the contents of a vial that still contains multiple doses of the vaccine).
- Given this vaccine does not contain preservative, and therefore has a short timeline for its use following first vial puncture, pooling of residual vaccine from two or three vials must occur as soon as possible - it is not recommended to save multiple vials with residual volume for use at one time (e.g., the end of the clinic).
- Perform hand hygiene before handling the vaccine. Strictly adhere to aseptic technique while handling the vaccine and minimize the number of vial punctures.
- Firmly and briskly wipe the surface of the rubber stopper with an alcohol swab for initial and subsequent uses, being sure to apply friction, and allow it to dry for at least 10 seconds.
- To assist with the withdrawal of residual vaccine from the vial, invert the vial and ensure the end of the needle is below fluid level and situated in the groove of the vial stopper.
- Once the residual vaccine is withdrawn, keep the needle in the vial when expelling air bubble(s) to minimize vaccine wastage.
- Check the syringe to ensure it contains the total 0.5 mL dose prior to administration.
- If not administered immediately, the syringe should be clearly labeled with the date and time of the vial with the shortest timeframe for use.